High-Dose Steroid No Benefit to Platelets in Preeclampsia

Share this content:
High-Dose Steroid No Benefit to Platelets in Preeclampsia
High-Dose Steroid No Benefit to Platelets in Preeclampsia

FRIDAY, June 10, 2016 (HealthDay News) -- High-dose methylprednisolone does not prevent platelet decline in women with preeclampsia and platelet counts below 150 × 109/L, according to a study published in the July issue of Obstetrics & Gynecology.

Olivier Pourrat, M.D., Ph.D., from the Centre d'Investigation Clinique in Poitiers, France, and colleagues conducted a randomized trial of 180 mg methylprednisolone or placebo administered in divided doses over 36 hours to women admitted for preeclampsia and platelet counts below 150 × 109/L. Thirty-six women were randomized to receive methylprednisolone and 34 to receive placebo.

The researchers found that 83 percent of the active group and 85 percent of the placebo group had platelet counts above 100 × 109/L at 36 hours after the first dose of study medication (relative risk, 0.98; 95 percent confidence interval, 0.80 to 1.20). One woman allocated to methylprednisolone had hyperglycemia, which was the only potentially study-related adverse event.

"In women with preeclampsia and platelet counts under 150 × 109/L, methylprednisolone was not effective in maintaining platelet counts above 100 × 109/L," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Florida Teen First Human Case of Another Mosquito-Borne Virus

Florida Teen First Human Case of Another Mosquito-Borne ...

First documented case of Keystone infection in a human

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

Illnesses reported in Illinois, Indiana, Kentucky, Michigan, Missouri, Ohio, and Tennessee

AAFP Still Recommends CRC Screening From Age 50 to 75

AAFP Still Recommends CRC Screening From Age 50 ...

Despite ACS change to start screening from age 45 years, AAFP agrees with USPSTF recommendation

is free, fast, and customized just for you!




Already a member?

Sign In Now »